Why the study?
The influence of digitalis use on mortality in patients with non-valvular atrial fibrillation remains controversial.
Does digitalis use increase all-cause death in patients with non-valvular atrial fibrillation?
Does digitalis use increase all-cause death in patients with non-valvular atrial fibrillation?
Digitalis use is not independently associated with increased all-cause mortality in patients with non-valvular atrial fibrillation after adjusting for clinical confounders.
Answers are grounded in this paper and cite their sources.
Should not yet change digitalis prescribing in NVAF; leaves open residual confounding behind prior mortality signals.
BACKGROUND: Because the influence of digitalis use on the death of patients with non-valvular atrial fibrillation (NVAF) remains controversial, a subanalysis of the J-RHYTHM Registry was performed. METHODS AND RESULTS: A consecutive series of outpatients with AF from 158 institutions was enrolled and followed for 2 years or until the occurrence of an event. Among 7,406 patients with NVAF, 7,018 (age, 69.7±10.0 years; men, 71.1%) with information on antiarrhythmic drug and digitalis use at baseline were divided into 2 groups based on digitalis use. The influence of digitalis on death was investigated using a propensity score-matching model. In 802 patients treated with digitalis, all-cause death was significantly higher than in 6,216 patients with no digitalis use during the 2-year follow-up period (4.4% vs. 2.4%, unadjusted P<0.001). Digitalis use was significantly associated with all-cause death in the crude model (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.28-2.68, P=0.001). However, after propensity score-matching, the association was not significant (HR 1.31, 95% CI 0.70-2.46, P=0.405). Older age, male sex, heart failure, coronary artery disease, and lower body mass index were significantly associated with all-cause death in NVAF patients treated with digitalis. CONCLUSIONS: Digitalis use was not independently associated with all-cause death, and several clinical confounding factors might contribute to increased mortality in NVAF patients treated with digitalis.
No takes yet. Share an insight, caveat, or question.
Kodani et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: